MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Beer, E. L.
Right arrow Articles by Voest, E. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Beer, E. L.
Right arrow Articles by Voest, E. E.

Vol. 57, Issue 6, 1152-1157, June 2000

Doxorubicin Impairs Crossbridge Turnover Kinetics in Skinned Cardiac Trabeculae after Acute and Chronic Treatment

Evert L. de Beer, Antonio E. Bottone, Jolanda van der Velden, and Emile E. Voest

Department of Medical Physiology and Sports Medicine, Utrecht University, Utrecht (E.L.d.B., A.E.B.); Laboratory for Physiology, Institute for Cardiovascular Research, Free University, Amsterdam (J.v.d.V.); and Department of Internal Medicine, University Hospital Utrecht, Utrecht (E.E.V.), The Netherlands

Crossbridge dynamics underlying the acute and chronic inotropic effects of doxorubicin (Dox) were studied by application of releasing length steps (amplitude, 0.5-10%) to skinned cardiac trabeculae. Acute incubation of trabeculae with 20 µM Dox for 30 min resulted in a decrease of the velocity of unloaded shortening (V0, from 9.3 ± 1.1 to 7.7 ± 0.7 µm/s, P < .05) and in an increase of the rate of force redevelopment (tau r, from 56 ± 4 to 65 ± 3 ms, P < .05) in response to step amplitudes ranging from 5 to 10%. In contrast, chronic Dox treatment in rats (2 mg/kg/week for 4 weeks) significantly impaired trabecular crossbridge dynamics after step releases of 0.5%. This was reflected by an increase of all time constants describing tension recovery: tau 1, from 10 ± 1 to 14 ± 1 ms; tau 2, from 65 ± 6 to 82 ± 6 ms; tau 3, from 92 ± 7 to 293 ± 67 ms; P < .05. In addition, V0 was decreased (from 8.6 ± 0.6 to 6.8 ± 0.3 µm/s, P < .05) and tau r was increased (from 67 ± 4 to 89 ± 3 ms; P < .05) in the slack-test. We found that chronic Dox treatment resulted in a shift from the "high ATPase" alpha -myosin heavy chain (MHC) isoform toward the "low-ATPase" beta -MHC isoform in the ventricles (control: alpha -MHC 79 ± 2% and beta -MHC 21 ± 2%; Dox-treated: alpha -MHC 53 ± 2% and beta -MHC 47 ± 2%; P < .05). The present results show that acute Dox incubation affects the detachment rate of crossbridges, which leads to a delayed relaxation and an arrest of crossbridges in strongly bound states. In contrast, chronic Dox treatment leads to an impairment of both the attachment and detachment rates in the crossbridge cycle, which may be explained by an altered MHC isoform composition in ventricular myocardium. Interfering with Dox-induced alterations of crossbridge kinetics may provide a new strategy to prevent Dox-associated cardiotoxicity.


Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Stem CellsHome page
G. Forte, F. Carotenuto, F. Pagliari, S. Pagliari, P. Cossa, R. Fiaccavento, A. Ahluwalia, G. Vozzi, B. Vinci, A. Serafino, et al.
Criticality of the Biological and Physical Stimuli Array Inducing Resident Cardiac Stem Cell Determination
Stem Cells, August 1, 2008; 26(8): 2093 - 2103.
[Abstract] [Full Text] [PDF]


Home page
Biophys. JHome page
S. A. Niederer, P. J. Hunter, and N. P. Smith
A Quantitative Analysis of Cardiac Myocyte Relaxation: A Simulation Study
Biophys. J., March 1, 2006; 90(5): 1697 - 1722.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
A. J. Chicco, D. S. Hydock, C. M. Schneider, and R. Hayward
Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity
J Appl Physiol, February 1, 2006; 100(2): 519 - 527.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics